This revealed that SHPRH was mutated in 2.4% (251/10443) of all samples profiled, with endometrial carcinoma (11.6%), cutaneous melanoma (5.9%), colorectal adenocarcinoma (4.9%) and stomach adenocarcinoma (4.1%) having the highest mutation rate other than lung cancer (LUAD = 3.9%) (Supplementary Fig. 2C). This evidence concerns the gene SHPRH and gastric adenocarcinoma.